Skip to main content
. Author manuscript; available in PMC: 2009 May 1.
Published in final edited form as: Cancer Res. 2008 May 1;68(9):3260–3268. doi: 10.1158/0008-5472.CAN-07-6215

Fig 4. Activation of Fv2E-PERK inhibits tumor growth of SW620 colon carcinoma cells.

Fig 4

(A) WB analysis of D-HEp3 and SW620 lysates for p- and total eIF2α respectively (left panel). Vehicle and AP20187 (1nM) treated lysates of SW620 cells expressing β-gal or Fv2E-PERK respectively were analyzed for active phosphorylated and inactive hypo-phosphorylated Fv2E-PERK and p-eIF2α levels respectively. Total eIF2α was used as a loading control (right panel). (B) T-Fv2E-PERK and SW-Fv2E-PERK cells treated with or without AP20187 were analyzed for p- and total-eIF2α levels by WB. (C) SW-Fv2E-PERK cells were treated with AP20187 for the indicated time points and analyzed by WB for cyclin D1 levels. GAPH was used as loading control. (D) SW620 cells expressing β-gal or Fv2E-PERK were inoculated on CAM at 0.5×106cells/CAM and treated daily with vehicle alone or with 0.005mg/kg of AP20187. Tumors were excised 7 days later and the number of tumor cells/nodule was determined as before. P<0.05 as determined by Mann-Whitney test.